3DµS
LIVE

Serial Number

79401832

Owner

Triastek, Inc.

Attorney

Alex Patel

Filing Date

Feb 22, 2024

Add to watchlist:

No watchlists yet
View on USPTO

3DµS Trademark

Serial Number: 79401832 • Registration: 7862559

3DµS is a trademark filed by Triastek, Inc. on February 22, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Triastek, Inc. (7 trademarks)

Room 101, 1F, Building 9,

Entity Type: 03

Trademark Details

Filing Date

February 22, 2024

Registration Date

July 15, 2025

Published for Opposition

April 15, 2025

Goods & Services

Machines for the pharmaceutical processing industry, namely, print heads for 3D printers for drugs and vaccine preparations, print heads for pharmaceutical drug and vaccine printing machines, industrial robots for conveying of drugs and vaccine preparations, and packaging machines for drugs and vaccine preparations; machines for the pharmaceutical processing industry, namely, for producing drug and vaccine capsules and tablets and mixing machines for drugs and vaccines; 3D printers * for pharmaceutical processing industry; * 3D bioprinters * for pharmaceutical processing industry *

Scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research services; testing of pharmaceuticals; research and development services in the field of medicines; development of pharmaceutical preparations and medicines; pharmaceutical research and development; pharmaceutical drug development services; pharmaceutical product evaluation; conducting early evaluations in the field of new pharmaceuticals; technical research in the field of pharmaceutical studies; quality testing of pharmaceutical product; advisory services relating to material testing

Veterinary preparations, namely, veterinary vaccines, greases for veterinary purposes, antibiotics for veterinary purposes, bacterial preparations for veterinary purposes, veterinary diagnostic reagents, antibodies for veterinary purposes, and anti-infective products for veterinary use; dietetic foods adapted for medical purposes; sugar for medical purposes; dental resin for temporary bridges, crowns and veneers; pharmaceutical preparations for the treatment of bone diseases; biological tissue cultures for medical purposes; fever blister treatment preparations; dysmenorrhea treatment preparations; pharmaceutical preparations for the central nervous system; oral analgesics; anticoagulants; tumor suppressing agents; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for inducing erections; stimulants for the central nervous system; pharmaceutical preparations for treating allergies; anti-diabetic pharmaceuticals; calcium channel blockers; medicinal preparations for the mouth to be applied in the form of tablets; pharmaceutical preparations for the prevention and treatment of cancer; niacinamide preparations for the treatment of acne; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating hypoglycemia; antihypertensives; chemotherapeutics; antivirals; anti-infectives; chemico-pharmaceutical preparations for the treatment of cancer, oncological diseases, cardiovascular and cerebrovascular diseases, respiratory diseases, genitourinary diseases, neurological diseases, immune system related diseases, gastrointestinal diseases, musculoskeletal diseases and endocrine metabolism-related diseases; living cells for medical use; parathyroid hormone preparations; contraceptive preparations; medicines for the treatment of cardiovascular and cerebrovascular diseases; hypnotic sedatives; pharmaceutical products for treating respiratory diseases

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Mar 3, 2026 NURC
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 26, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 11, 2026 FICS
LIMITATION FROM THE IB EXAMINED AND ENTERED
Feb 11, 2026 LIME
FINAL DISPOSITION PROCESSED
Feb 11, 2026 FIMP
CORRECTION UNDER SECTION 7 - PROCESSED
Feb 11, 2026 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 11, 2026 APRE
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 22, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 7, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 7, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 15, 2025 FICR
LIMITATION OF GOODS RECEIVED FROM IB
Aug 22, 2025 LIMG
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 15, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 15, 2025 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 25, 2025 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
May 15, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 15, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 15, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 9, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 21, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 25, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 25, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 25, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 25, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 24, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 17, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 17, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 17, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 20, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 17, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 16, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 14, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 13, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 19, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 19, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 15, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 8, 2024 REPR